Hansoh Pharmaceutical’s two eagerly awaited ADCs have continued to deliver support for partner GSK’s promotion of them as a “priority asset.” The newest evidence of the efficacy of the therapies is from a Chinese phase 3 trial of the ADC targeting B7-H3, risvutatug rezetecan (ris-rez). The trial hit its primary endpoint of overall survival in patients with advanced or relapsed small-cell lung cancer (SCLC) when compared against standard-of-care chemotherapy, according to a July 10 release.
The two companies cheered the triumph as the “first positive phase 3 overall survival data reported for a B7-H3-targeted ADC in any tumor type.” The release didn’t provide any specific information, but Hansoh will use the results to embark on an approval push in China.
The latest findings, B7-H3 noted, “Build upon the ever-expanding body of evidence showing the promising clinical activity and tolerable safety profile of ris-rez in these patients.”
“Together, with other data generated to date, [these results] further support the potential of B7-H3 as a promising target across lung cancer and other solid tumors and reinforce our continued development of ris-rez to improve standard of care in areas of high unmet need,” GSK’s Global Head of Oncology, Hesham Abdullah, said in the release.
Outside Greater China, GSK has the rights to develop ris-rez and a B7-H4-directed ADC called mo-rez from Hansoh. The British pharma is conducting its own studies on ris-rez across various cancers, such as a phase 3 trial in extensive-stage small-cell lung cancer that’s set to read out in 2027 and an independent late-stage trial in genitourinary cancer which will begin later this year.
In April, GSK presented us with “extremely exciting” phase 1 data in platinum-resistant ovarian cancer and endometrial cancer with its other ADC, mo-rez. At the time, the firm stated that it felt this was good enough proof to begin to plan five late-stage trials of the ADC in the coming months.
Abdullah, in that announcement, called both assets “priority assets” for GSK. That oncology chief started pumpin’ and hawkin’ as early as October 2025, when he said to Fierce, “Stay tuned” for the Big Pharma to start its own build of data for the assets.
Hansoh and GSK have reached an important milestone after their partnered antibody-drug conjugate (ADC) achieved positive Phase 3 results in China. The successful study strengthens confidence in the therapy and supports GSK’s view of the treatment as one of its priority assets. For Hansoh, the achievement highlights the growing impact of its research capabilities and strategic collaborations in advancing innovative cancer therapies.
Phase 3 Results Mark a Significant Milestone
The successful Phase 3 trial represents a major achievement for Hansoh and its global development partner, GSK. Meeting the study objectives provides strong clinical evidence supporting the therapy’s effectiveness and safety, bringing the ADC one step closer to potential regulatory submissions and commercial availability.
Positive late-stage clinical results also reinforce confidence in the long-term value of the partnership.
Impact on the Oncology Market
Positive clinical outcomes from Hansoh’s partnered ADC reflect growing momentum within the oncology sector, where targeted therapies continue to improve treatment options for patients. Antibody-drug conjugates combine precise tumor targeting with potent therapeutic agents, making them an increasingly attractive approach for cancer treatment.
As additional clinical evidence becomes available, the therapy could play an important role in expanding treatment choices for eligible patients.
Next Steps for Development
Following the successful Phase 3 study, Hansoh and GSK are expected to advance regulatory submissions while preparing manufacturing and commercialization strategies. Additional studies may also explore broader indications and combination treatment opportunities.
Continued collaboration will be essential to bringing the therapy to patients in multiple global markets.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
